These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30658922)

  • 1. Clinical profile of women diagnosed with Fabry disease non receiving enzyme replacement therapy.
    Barba-Romero MÁ; Serena J; Puig JM; Valverde C V; Climent V; Herrero JA; Huertas R; Torra R
    Med Clin (Barc); 2019 Jul; 153(2):47-55. PubMed ID: 30658922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
    Rosa Neto NS; Bento JCB; Pereira RMR
    Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported experience with Fabry disease and its management in the real-world setting: results from a double-blind, cross-sectional survey of 280 respondents.
    Berry L; Walter J; Johnson J; Alton J; Powers J; Llòria X; Koulinska I; McGee M; Laney D
    Orphanet J Rare Dis; 2024 Apr; 19(1):153. PubMed ID: 38605390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.
    Vujasinovic M; Tepes B; Vujkovac B; Cokan Vujkovac A; Tretjak M; Korat V
    Wien Klin Wochenschr; 2015 Dec; 127(23-24):931-4. PubMed ID: 25835592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for health-related quality of life and its determinants in Fabry disease: A cross-sectional multicenter study.
    Winter Y; Hilz M; Beuschlein F; Tsukimura T; Seifritz E; Lenders M; Brand E; Hennermann JB; Nowak A
    Mol Genet Metab; 2023 Nov; 140(3):107692. PubMed ID: 37703724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey.
    Barba-Romero MÁ; Pintos-Morell G
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27886142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients.
    Germain DP; Fouilhoux A; Decramer S; Tardieu M; Pillet P; Fila M; Rivera S; Deschênes G; Lacombe D
    Clin Genet; 2019 Aug; 96(2):107-117. PubMed ID: 30941742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
    Tsuboi K; Yamamoto H
    BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland.
    Nowicki M; Komar M; Kusztal M; Mizia-Stec K; Liberek T; Małyszko J; Muras-Szwedziak K; Pawlaczyk K; Podolec P; Sławek J
    F1000Res; 2021; 10():841. PubMed ID: 34745562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.
    Kim JH; Lee BH; Hyang Cho J; Kang E; Choi JH; Kim GH; Yoo HW
    J Hum Genet; 2016 Nov; 61(11):923-929. PubMed ID: 27334365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.
    Biegstraaten M; Arngrímsson R; Barbey F; Boks L; Cecchi F; Deegan PB; Feldt-Rasmussen U; Geberhiwot T; Germain DP; Hendriksz C; Hughes DA; Kantola I; Karabul N; Lavery C; Linthorst GE; Mehta A; van de Mheen E; Oliveira JP; Parini R; Ramaswami U; Rudnicki M; Serra A; Sommer C; Sunder-Plassmann G; Svarstad E; Sweeb A; Terryn W; Tylki-Szymanska A; Tøndel C; Vujkovac B; Weidemann F; Wijburg FA; Woolfson P; Hollak CE
    Orphanet J Rare Dis; 2015 Mar; 10():36. PubMed ID: 25885911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS).
    Barba-Romero MÁ; Rivera-Gallego A; Pintos-Morell G;
    Int J Clin Pract; 2011 Aug; 65(8):903-10. PubMed ID: 21679285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hearing loss in adult patients with Fabry disease treated with enzyme replacement therapy.
    Suntjens EB; Smid BE; Biegstraaten M; Dreschler WA; Hollak CE; Linthorst GE
    J Inherit Metab Dis; 2015 Mar; 38(2):351-8. PubMed ID: 25395255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.
    Whybra C; Kampmann C; Krummenauer F; Ries M; Mengel E; Miebach E; Baehner F; Kim K; Bajbouj M; Schwarting A; Gal A; Beck M
    Clin Genet; 2004 Apr; 65(4):299-307. PubMed ID: 15025723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey.
    Morand O; Johnson J; Walter J; Atkinson L; Kline G; Frey A; Politei J; Schiffmann R
    Adv Ther; 2019 Oct; 36(10):2866-2880. PubMed ID: 31435831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic and clinical findings in patients with Fabry disease during long-term enzyme replacement therapy: a nationwide Danish cohort study.
    Madsen CV; Bundgaard H; Rasmussen ÅK; Sørensen SS; Petersen JH; Køber L; Feldt-Rasmussen U; Petri H
    Scand Cardiovasc J; 2017 Aug; 51(4):207-216. PubMed ID: 28545342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
    Hopkin RJ; Cabrera G; Charrow J; Lemay R; Martins AM; Mauer M; Ortiz A; Patel MR; Sims K; Waldek S; Warnock DG; Wilcox WR
    Mol Genet Metab; 2016 Sep; 119(1-2):151-9. PubMed ID: 27510433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.